ALNY stock icon

Alnylam Pharmaceuticals
ALNY

$260.51
0.2%
 

About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Employees: 2,100

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 42 analysts
0
News positive %
of 18 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

51% more call options, than puts

Call options by funds: $461M | Put options by funds: $304M

36% more repeat investments, than reductions

Existing positions increased: 199 | Existing positions reduced: 146

33% more funds holding in top 10

Funds holding in top 10: 6 [Q4 2023] → 8 (+2) [Q1 2024]

1% less funds holding

Funds holding: 485 [Q4 2023] → 482 (-3) [Q1 2024]

4% less first-time investments, than exits

New positions opened: 71 | Existing positions closed: 74

3.85% less ownership

Funds ownership: 93.18% [Q4 2023] → 89.33% (-3.85%) [Q1 2024]

25% less capital invested

Capital invested by funds: $22.4B [Q4 2023] → $16.8B (-$5.56B) [Q1 2024]

Research analyst outlook

42 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$150
42%
downside
Avg. target
$239
8%
downside
High target
$400
54%
upside

42 analyst ratings

26 positive
62%
16 neutral
38%
negative
0%
Morgan Stanley
Michael Ulz
2%downside
$255
Equal-Weight
Maintained
12 Jul 2024
Canaccord Genuity
Whitney Ijem
37%upside
$357
Buy
Maintained
8 Jul 2024
JP Morgan
Jessica Fye
5%downside
$248
Neutral
Maintained
3 Jul 2024
Cantor Fitzgerald
Olivia Brayer
42%downside
$150
Neutral
Reiterated
1 Jul 2024
UBS
Eliana Merle
11%upside
$288
Buy
Maintained
28 Jun 2024

Financial journalist opinion

Based on 18 articles about ALNY published over the past 30 days